Protocols
ADICET-ADI-001-BCELL Phase I OPEN TO ACCRUAL
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies, in Monotherapy and Combination with IL-2.
ALLOGENE-ALLO-501A-201 Phase I OPEN TO ACCRUAL
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of Allo-501A and Anti-CD19 Allogeneic CAR-T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
BEIGENE-BGB-11417-105 Phase I/II OPEN TO ACCRUAL
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination with Dexamethasone and Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
CELGENE-CC-92328-MM-001 Phase I OPEN TO ACCRUAL
A Phase 1, Multi-Center, Open-Label, Dose Finding Study of CC-92328 in Subjects with Relapsed and/or Refractory Multiple Myeloma
CHIMAGEN-CMG1A46-US01 Phase I/II OPEN TO ACCRUAL
A Phase 1/2, First in Human, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Triple-specific T-cell Engager CMG1A46 in Adult Patients with Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies
ECOG-EA9152-ALL Phase I/II OPEN TO ACCRUAL *
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
IIT-ATALLAH-MCW-XEN21 Phase I OPEN TO ACCRUAL
A Phase 1 Study of XmAb18968 (CD3-CD38) for the Treatment of Patients with Relapsed/Refractory CD38 Positive Acute Leukemia and T Cell Lymphoblastic Lymphoma
IIT-SHAH-IL7-IL15-CD20-19 Phase I/II OPEN TO ACCRUAL
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
JUNO-017004-TRANSCEND-CLL Phase I/II OPEN TO ACCRUAL
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
KRONOS-KB-LANRA-1001 Phase I/II OPEN TO ACCRUAL
A Phase 1b/2 Study of the Safety, PK, PD and Preliminary Efficacy of the FLT3 Inhibitor Gilteritinib, in Combination with the Selective SYK Inhibitor Lanraplenib (KB-9876), in Patients with FLT3-mutated Relapsed or Refractory AML
MEI-ME-522-001 Phase I OPEN TO ACCRUAL
A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B-cell Malignancies or Acute Myeloid Leukemia after Failure of Prior Standard Therapies and Voruciclib in Combination with Venetoclax in Subjects with Relapsed and/or Refractory Acute Myeloid Leukemia
SORRENTO-STI-6129-001 Phase I/II OPEN TO ACCRUAL
A Phase 1b/2a, Open-label, Dose-escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Systemic AL Amyloidosis
TAKEDA-TAK-981-1503 Phase I/II OPEN TO ACCRUAL
Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination with Monoclonal Antibodies in Adult Patients with Relapsed and/or Refractory Multiple Myeloma
TENEOBIO-TENEOTWO-TNB486-001 Phase I OPEN TO ACCRUAL
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody, in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
TENEOBIO-TNB-383B Phase I OPEN TO ACCRUAL
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma